AbbVie's Allergan Files US Application AGN-190584 For Presbyopia

Loading...
Loading...
  • Allergan, an AbbVie Inc (NYSE: ABBV), has submitted a marketing application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021.
  • Presbyopia is a common and progressive eye condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40.
  • AGN-190584 is an investigational optimized formulation of pilocarpine, a cholinergic muscarinic receptor agonist, which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle.
  • Price Action: ABBV is down 0.95% at $107.66 in market trading hours on the last check Thursday.
Posted In: BiotechNewsHealth CareFDAGeneralpresbyopia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...